Cargando…
P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429680/ http://dx.doi.org/10.1097/01.HS9.0000847228.68024.43 |
| _version_ | 1784779533779468288 |
|---|---|
| author | Xie, Y. Tang, Y. Zheng, W. Ping, L. Lin, N. Tu, M. Zhang, C. Ying, Z. Liu, W. Deng, L. Wu, M. Mi, L. Du, T. Wang, X. Zhu, J. Song, Y. |
| author_facet | Xie, Y. Tang, Y. Zheng, W. Ping, L. Lin, N. Tu, M. Zhang, C. Ying, Z. Liu, W. Deng, L. Wu, M. Mi, L. Du, T. Wang, X. Zhu, J. Song, Y. |
| author_sort | Xie, Y. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429680 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94296802022-08-31 P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL Xie, Y. Tang, Y. Zheng, W. Ping, L. Lin, N. Tu, M. Zhang, C. Ying, Z. Liu, W. Deng, L. Wu, M. Mi, L. Du, T. Wang, X. Zhu, J. Song, Y. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429680/ http://dx.doi.org/10.1097/01.HS9.0000847228.68024.43 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Xie, Y. Tang, Y. Zheng, W. Ping, L. Lin, N. Tu, M. Zhang, C. Ying, Z. Liu, W. Deng, L. Wu, M. Mi, L. Du, T. Wang, X. Zhu, J. Song, Y. P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL |
| title | P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL |
| title_full | P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL |
| title_fullStr | P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL |
| title_full_unstemmed | P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL |
| title_short | P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL |
| title_sort | p1090: camrelizumab (cam) combined with gemox chemotherapy results in high complete metabolic response rates in relapsed/refractory classic hodgkin lymphoma (chl): a phase ii trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429680/ http://dx.doi.org/10.1097/01.HS9.0000847228.68024.43 |
| work_keys_str_mv | AT xiey p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT tangy p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT zhengw p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT pingl p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT linn p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT tum p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT zhangc p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT yingz p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT liuw p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT dengl p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT wum p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT mil p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT dut p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT wangx p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT zhuj p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial AT songy p1090camrelizumabcamcombinedwithgemoxchemotherapyresultsinhighcompletemetabolicresponseratesinrelapsedrefractoryclassichodgkinlymphomachlaphaseiitrial |